What has been exciting is Mundipharma's support to research the current unmet needs in patients with asthma, and to truly and openly look at models that actually improve the management of those patients to get the best outcome.

David Price, Professor of Primary Care Respiratory Medicine, Primary Care Respiratory Society UK
 

Corporate Social Responsibility

At Mundipharma we are committed to developing a diverse portfolio of medicines and devices that meet societal needs. We aim to conduct our business in an ethical, transparent and responsible way, doing what’s right for our employees and partners, while contributing to the communities within which we operate. We look at things from a different perspective and are experts at identifying and developing the potential of medical innovations to help improve patient’s lives in meaningful ways.

Our responsibility in opioid management
We have a proud, 35-year heritage in pain management across Europe and are committed to enabling healthcare professionals to treat their patients in pain safely and responsibly. As an organisation that manufactures opioids, we believe we have a responsibility to take measures to minimise the risk of misuse and abuse of these medicines while not depriving the patients that need them.

We recognise that misuse and abuse of pain medications can lead to addiction, overdose and death, and we are aware of the public health risk these potent medications can create, especially when they are diverted, misused and/or abused. That’s why we are committed to reducing the risk of misuse and abuse through a secure supply chain, appropriate education of healthcare professionals, responsible sales and marketing and close collaboration with government authorities and medical organisations.

We fund educational initiatives in line with industry regulations that clearly communicate the facts about opioid medicines in a balanced and responsible manner, outlining both risks and benefits and helping to ensure that our medicines are prescribed only to the right patient for the right reasons.

We are also committed to finding new approaches to the management of pain, including research into new mechanisms and medicines with the potential to reduce or avoid the need for opioids.

In Europe, heroin and opioid addiction is an emerging problem in our communities, and this population is often overlooked. We are encouraged that our medicines also play an important role in addiction rehabilitation treatment programmes to help this underserved community